NORCURON Drug Patent Profile

When do Norcuron patents expire, and what generic alternatives are available?

Norcuron is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in NORCURON is vecuronium bromide. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norcuron

A generic version of NORCURON was approved as vecuronium bromide by MEITHEAL on August 25^th, 1999.

Summary for NORCURON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	3
Patent Applications:	2,001
DailyMed Link:	NORCURON at DailyMed

Recent Clinical Trials for NORCURON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chinese PLA General Hospital	Phase 4
Ruijin Hospital	Phase 4
West China Hospital	Phase 4

See all NORCURON clinical trials

US Patents and Regulatory Information for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984		DISCN	Yes	No
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992		DISCN	Yes	No

Expired US Patents for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984

International Patents for NORCURON

See the table below for patents covering NORCURON around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	676708
Brazil	6677320
Switzerland	564565
Germany	1593142
Denmark	114688

Last updated: April 25, 2026

NORCURON (nocuronium bromide): What drives market dynamics and how has its financial trajectory moved?

What is NORCURON’s market position and how does it compete?

NORCURON is a neuromuscular blocking agent (NMBA) branded as nocuronium bromide for perioperative anesthesia use. Its market dynamics are shaped by four forces: (1) hospital purchasing via tenders and formulary decisions, (2) generic entry economics in established markets, (3) the drug class’s clinical substitution patterns, and (4) regulation and supply continuity for injectable anesthetic inputs.

Class and use case

• Indication: perioperative skeletal muscle relaxation for intubation and general anesthesia.
• Buyers: hospitals and anesthesia service lines; procurement decisions focus on price per dose, availability, and label compatibility with local practice.

Competitive set

• Direct competition comes from other aminosteroid NMBAs and benzylisoquinolinium competitors, but procurement typically prioritizes:
  • therapeutic substitution within NMBA classes (same functional role in anesthesia),
  • unit economics (dose cost, vial size, wastage),
  • tender pricing and distribution terms.
• Competitive brands and generics typically compete on net price, not differentiated efficacy.

How do procurement and tendering affect demand stability?

NORCURON demand is tied to surgical volume and anesthesia utilization, but hospital buying patterns create distinct near-term dynamics:

1) Tender cycles smooth revenue variability

• Hospital contracts commonly run through multi-month or multi-year procurement cycles.
• Once a hospital formulary is set, switching branded NMBAs often requires a new clinical or commercial justification.

2) Price compression accelerates after generic availability

• After patent/market exclusivity windows close in specific geographies, generic nocuronium bromide entry tends to reduce branded net pricing through tender pressure.
• The most visible effect is downward movement in realized price, not a collapse in volumes.

3) Supply reliability is a purchase driver

• NMBAs are used in time-sensitive operating room settings.
• Procurement tends to overweight supply continuity, which can cause temporary reallocation between suppliers during shortages, even when pricing differs.

What are the market drivers specific to nocuronium bromide?

Within anesthesia, NMBAs are used for:

• rapid muscle relaxation,
• intubation conditions,
• maintenance of paralysis during surgery.

For nocuronium bromide, the market’s “value proposition” for purchasing is usually operational:

• consistent onset and duration in real-world anesthesia practice,
• dosing flexibility aligned with typical perioperative dosing workflows,
• injectable presentation compatible with routine anesthesia protocols.

In practice, these factors limit “winner-takes-most” differentiation. Once generics are available at scale, the branded product’s market share usually depends on contracting relationships and procurement inertia.

---

How has NORCURON’s financial trajectory progressed across key phases?

What happens to revenue when exclusivity ends?

Financial trajectories for branded injectable NMBAs typically follow a three-stage path: 1) Exclusivity protection: branded pricing holds; revenue tracks surgical volume and market share growth or stability. 2) Generic entry: net price declines faster than volume, driving revenue erosion. 3) Post-switch stabilization: once tenders lock in preferred products (generic or alternate brands), revenue stabilizes at a lower level for the remaining branded base.

For NORCURON, the key financial implication for investors is that volume declines tend to lag price compression. The revenue slope usually steepens around the first sustained generic procurement wins.

What is the expected margin and earnings profile once branded pricing resets?

Injectable NMBAs are logistics- and distribution-sensitive. When branded net pricing resets downward:

• gross margin compresses unless offset by cost reductions,
• sales and distribution efficiency matters more because the addressable share narrows to accounts that retain the brand.

Net income impact generally follows:

• revenue decline from price and share,
• partly offset by lower marketing intensity (often reduced after generic substitution accelerates),
• residual margins depend on whether branded product remains contracted in enough hospitals to cover fixed supply economics.

What would an evidence-based financial trajectory require (and what is available here)?

A complete, accurate financial trajectory requires audited revenue by geography and timeline, or at minimum:

• historical sales data (e.g., company filings, prescription data with mapping),
• the dates and geographies of generic launches that triggered tender-driven resets.

In the absence of sourced numeric sales history for NORCURON in the materials provided here, a fully data-validated financial trajectory cannot be produced.

---

Market dynamics by geography: where changes usually show up first

What regions typically drive early adoption of generic nocuronium bromide?

Market substitution patterns usually begin in:

• high tender-coverage markets with established generic procurement pathways,
• jurisdictions with strong substitution rules or competitive tender environments,
• markets where multiple biosimilar-like hospital switching programs exist for generics.

For branded NMBAs, the earliest visible revenue hits usually come through:

• large hospital group tenders,
• national or regional formularies,
• distributor shelf reallocations.

How do hospital formulary and reimbursement shape the timing?

• If formulary placement already exists, switching is primarily driven by procurement.
• In systems with reimbursement-driven economics, price-based substitution can occur quickly once a generic is accepted for coverage.

---

Key business implications

Where does NORCURON sit in the “investment vs. defend” decision tree?

• If NORCURON is still contracted in a meaningful base of hospitals post-generic entry, revenue can remain stable at a reduced level.
• If tender wins have shifted materially to competitors, the product becomes a “defense of residual share” story rather than a growth story.

What levers determine whether branded revenue stabilizes or continues falling?

The main levers are:

• net price strategy and contract renewal terms,
• supply continuity and distributor commitments,
• surgical volume trends in hospital systems still using the brand,
• competitive tender intensity and availability of alternative NMBA products.

---

Key Takeaways

• NORCURON’s market dynamics are dominated by hospital tender cycles, price compression after generic entry, and operational procurement requirements for injectable anesthesia inputs.
• The revenue trajectory for branded NMBAs typically shows faster net price decline than volume decline, followed by stabilization once formularies shift.
• A fully numeric, evidence-based financial trajectory for NORCURON cannot be stated from the information provided in this prompt, so conclusions here focus on structurally observable dynamics rather than audited revenue figures.

---

FAQs

1) Is NORCURON’s demand primarily driven by surgical volume?

Yes. Use tracks perioperative procedures and anesthesia utilization, with near-term fluctuations modulated by hospital purchasing cycles.

2) Does generic competition mainly impact NORCURON through price or volume?

Price typically compresses first via tender pricing; volume declines often follow as hospital contracts switch preferred suppliers.

3) Why do hospital tenders matter more than clinical differentiation for NMBAs?

NMBA functional role is similar across substitutable options, so procurement focuses on net cost per use, availability, and contract terms.

4) What risks most affect revenue continuity for injectable NMBAs?

Supply continuity and tender-driven supplier shifts are the main near-term risks in operating room procurement settings.

5) What drives stabilization after generics enter?

Once formularies and multi-hospital contracts lock preferred products, branded revenue often stabilizes at a residual level rather than continuing to fall indefinitely.

---

References

[1] No sources were provided in the prompt that contain NORCURON financial performance, sales history, launch dates, or geographic generic-entry timing.